Newcomer Lee Nisley
SEC insider (Form 3/4/5 filer). CIK 0001788981. Director at Coherus Oncology, Inc. (CHRS) and 1 other issuer. 4 reported Form 4/5 transactions since Sep 2024; latest on Jun 5, 2026. Located in SALT LAKE CITY, UT.
Companies Newcomer Lee Nisley has filed insider reports for
- Coherus Oncology, Inc. (CHRS): Director
- MYRIAD GENETICS INC (MYGN): Director
Newcomer Lee Nisley
CIK: 0001788981
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)4 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Jun 5, 2026CHRS
Coherus Oncology, Inc.
AwardDirect30K shares- - Jun 4, 2026MYGN
MYRIAD GENETICS INC
AwardDirect59.7K shares- - Jun 12, 2025CHRS
Coherus Oncology, Inc.
AwardDirectStock Option (Right to Buy)
112K shares- - Jun 5, 2025MYGN
MYRIAD GENETICS INC
AwardDirect49.8K shares-
1-4 of 4 transactions